MARKET

KDMN

KDMN

KADMON
NYSE

Real-time Quotes | Nasdaq Last Sale

4.980
+0.240
+5.06%
After Hours: 5.01 +0.03 +0.60% 17:53 12/11 EST
OPEN
4.760
PREV CLOSE
4.740
HIGH
5.02
LOW
4.741
VOLUME
2.55M
TURNOVER
--
52 WEEK HIGH
5.02
52 WEEK LOW
1.630
MARKET CAP
794.48M
P/E (TTM)
-6.0007
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of KDMN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

KDMN News

  • The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares
  • Benzinga.1d ago
  • The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
  • Benzinga.4d ago
  • The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
  • Benzinga.4d ago
  • Kadmon (KDMN) Investor Presentation - Slideshow
  • Seeking Alpha - Article.6d ago

More

Industry

Pharmaceuticals
+0.17%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About KDMN

Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company's other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company's portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson's disease.
More

Webull offers Kadmon Holdings Inc (KDMN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.